ABSTRACT Diabetes is a significant global chronic disease characterised by elevated mortality and disability rates due to persistent infections resulting from refractory wounds. Currently, effective treatment strategies are lacking. Adipose‐derived stem cell extracellular vesicles (ADSC‐EVs) have been shown to promote skin wound healing; however, their clinical application is impeded by low yield and heterogeneity. We successfully isolated high‐yield extruded nanovesicles from adipose stem cells (ADSC‐NVs), achieving yields over 30 times greater than those of ADSC‐EVs while maintaining similar mor‐phological characteristics. Our findings indicate that ADSC‐NVs exhibit a dose‐dependent en‐hancement of proliferation and migration in primary human dermal fibroblasts (HDF) in vitro. Notably, the expression levels of proliferating cell nuclear antigen (PCNA), collagen type I (COL‐I) and collagen type III (COL‐III) were significantly upregulated in HDF following treatment with ADSC‐NVs. RNA‐seq analysis further revealed that the differentially expressed genes (DEGs) shared between the ADSC‐NVs group and control group were predominantly enriched in the Wnt signalling pathway. Consistently, ADSC‐NVs facilitate efficient diabetic wound healing while promoting proliferation and inhibiting inflammation via the Wnt/β‐catenin signalling pathway. In summary, high‐yield ADSC‐NVs represent a promising alternative to ADSC‐EVs for enhancing diabetic wound healing, providing novel insights and methodologies for improving therapeutic outcomes.
Yao et al. (2025) studied this question.